[Form 4] Rigetti Computing, Inc. Insider Trading Activity
Rigetti Computing director Michael S. Clifton reported insider sales on 09/12/2025 under a Rule 10b5-1 plan. Clifton sold a total of 75,000 shares in two transactions: 25,000 shares at $17.00 and 50,000 shares at a weighted average price of $20.003. After these sales the filing shows beneficial ownership of 653,766 shares. The filing also reports ownership of 28,812 warrants with an $11.50 exercise price; the warrants and related underlying shares are noted as fully vested and exercisable. The Form 4 was signed by an attorney-in-fact on 09/15/2025.
- Transactions executed under a Rule 10b5-1 plan, indicating prearranged trades rather than opportunistic insider timing
- Warrants (28,812) are fully vested and exercisable, clarifying future potential for exercise-based liquidity or dilution
- Director sold 75,000 shares on 09/12/2025, which reduces his reported beneficial ownership
- Weighted-average sale price includes higher-price executions ($20.00–$20.02), showing partial disposition at varying price points
Insights
TL;DR: Director sold 75,000 RGTI shares via a 10b5-1 plan; remaining beneficial stake ~653,766 shares; warrants fully vested.
The reported sale of 75,000 shares on a single date under an established Rule 10b5-1 plan indicates a prearranged disposition rather than an ad-hoc trade. The transactions occurred at $17.00 and a weighted average of $20.003, reducing reported beneficial ownership to 653,766 shares. From a capital markets perspective, sales under 10b5-1 plans typically carry less informational content about insider views, but the size of the sale relative to holdings is relevant for modeling insider liquidity and potential downward supply pressure.
TL;DR: Trades executed under a documented 10b5-1 plan and signed by an attorney-in-fact; warrants are fully exercisable.
The filing documents compliance with procedural safeguards: adoption of a Rule 10b5-1 plan (March 10, 2025) and execution via attorney-in-fact signature, which supports formality and advance planning. The existence of 28,812 warrants at an $11.50 exercise price, noted as fully vested and exercisable, is important for assessing potential future dilution. No other governance issues or amendments are reported in this Form 4.